_______________________________________________



		     SECURITIES AND EXCHANGE COMMISSION
		     
			  Washington, D. C. 20549
			   
				FORM 10-Q/A2


	    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF
		   THE SECURITIES EXCHANGE ACT OF 1934.


	      For the quarterly period ended January 31, 1995



Commission File Number 0-944

			    POSSIS MEDICAL, INC.

			 2905 Northwest Boulevard

		     Minneapolis, Minnesota 55441-2644

			      (612) 550-1010


A Minnesota Corporation                         IRS Employer ID No. 41-0783184

		     _________________________________



Indicate by check mark whether the Registrant (1) has filed all reports 
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 
1934 during the preceding 12 months (or for such shorter period that the 
Registrant was required to file such reports), and (2) has been subject to 
such filing requirements for the past 90 days.  Yes_X_ No___

The number of shares outstanding of the Registrant's Common Stock, $.40 par 
value, as of March 13, 1995 was 9,917,338.

			  
		    ________________________________

				   1

This amendment contains only PART II, Item 6.  Exhibits and Reports on Form 8-K 
of the Report on Form 10-Q for the quarterly period ended January 31, 1995, 
originally filed March 17, 1995. Only the item being amended is included in 
this filing; said item is the Exhibit 10 Supply and Distribution Agreement with
Bard Vascular Systems Division, C.R. Bard, Inc., amended to include Exhibit B 
thereto, which was previously subject to registrant's Request for 
Confidential Treatment.       






































				       2

ITEM 6. Exhibits and Reports on Form 8-K

	(a)     Exhibits

		  Exhibit 10:     Supply and Distribution Agreement with Bard
				  Vascular Systems Division, C.R. Bard, Inc.  
				  This Exhibit 10 contains information subject 
				  to a Request for Confidential Treatment, 
				  filed with the Commission on March 17, 1995.

	(b)     Reports on Form 8-K

		  During the quarter ended January 31, 1995, a report on Form
		  8-K dated December 6, 1994, reporting under Item 5, the U.S. 
		  Food and Drug Administration approval of expansion of the 
		  Company's Phase I clinical trials of its Perma-Flow Coronary 
		  Bypass Graft was filed.

























				      3

SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the 
registrant has duly caused this report to be signed on its behalf by the 
undersigned thereunto duly authorized.




			      POSSIS MEDICAL, INC.


DATE:     May 19, 1995        BY:      /s/  Robert G. Dutcher          
				       ROBERT G. DUTCHER
				       President and Chief Executive Officer



DATE:     May 19, 1995        BY:      /s/   Russel E. Carlson          
				       RUSSEL E. CARLSON
				       Vice President of Finance
				       Chief Financial and Accounting Officer 





























				      4